August 5, 2019 | Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction

February 13, 2019 | Washington Business Journal, Gaithersburg biotech is raising millions to treat nicotine-related diseases — and help smokers quit
Matt Kalnik wants to make smoking less addictive. His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. Read full story

February 7, 2019 | Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for Reducing Lung Cancer in High Risk Smokers


October 31, 2018 | Selected a Top 500 startup from 4,500 contenders by Hello Tomorrow’s Global Challenge, a renowned deep tech startup competition intended to propel innovation from lab to market to help solve the world’s toughest challenges.

September 5, 2018 | Antidote Therapeutics Receives Orphan Drug Designation for ATI-1013 for the Treatment of Buerger’s Disease

July 30, 2018 | Preclinical proof-of-concept of Antidote Therapeutics’ nicotine-degrading enzyme program as a potential new treatment for nicotine addiction published in BMC Biotechnology

March 2018Pre-clinical Research services agreement to evaluate ATI-1013’s efficacy in reducing nicotine’s cardiovascular effects in rats

January 2018 | Sponsored Research and Option agreement with The University of Texas, Austin for optimization of nicotine degrading enzymes


December 2017Entered commercial evaluation agreement with Clearview Healthcare Partners

August 2017Investment from Novartis Venture Funds

July 2107Entered manufacturing services agreement for ATI-1013

June 2017Investment from Maryland’s TEDCO

March 2017Award of a Phase 1 Small Business Innovative Research grant from NIDA for nicotine-degrading enzymes

February 2017National stage patent application filings for “Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning”


November 2015Sponsored Research and Option Agreement with The Scripps Research Institute for in vivo evaluation of nicotine degrading enzymes

August 2015Collaboration and Option Agreement with Blink Biomedical for discovery of antibodies (IgG) against nicotine

June 2015Began enrollment in ATI-1501 clinical research study


December 2014Entered multiple Sponsored Research and Option Agreements with Strategic Alliance collaborative partners: The University of Minnesota and Minneapolis Medical Research Foundation, The Scripps Research Institute, The University of California at San Diego, BliNK Biomedical, Cato Research, and BioFactura.

September 2014Awarded $8.5 million Strategic Alliance grant for “Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs” from the National Institute on Drug Abuse (NIDA)